George Lundberg, MD Editor in Chief at Cancer Commons
-
July 11, 2020
Adult H3K27M-Mutant Diffuse Midline Glioma with Gliomatosis Cerebri Growth Pattern: Case Report and Review of the Literature Bookmark
George Lundberg, MDResearch paper from the International Journal of Surgery Case Reports curated by Editor in Chief George Lundberg, MD, who notes:
We present here an open-access case report and literature review of a patient with the H2K27M-mutant variant of diffuse midline glioma.
Go to full paper published in the International Journal of Surgery Case Reports.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
July 11, 2020
Diffuse Midline Gliomas Bookmark
George Lundberg, MDCurated by Editor in Chief George Lundberg, MD, who notes:
This outline from the National Cancer Institute provides an overview of diffuse midline gliomas. Diffuse intrinsic pontine gliomas (DIPG), which occur primarily in children, are a subset of diffuse midline gliomas. -
May 30, 2020
China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Bookmark
George Lundberg, MDPress release from Novocure curated by Editor in Chief George Lundberg, MD, who notes:
Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.
Go to full article published by Novocure on Business Wire.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
What Have I Learned in More Than Half a Century in Cancer Medicine? Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
“Patients with cancer need to be embraced with love and compassion. They need caring beyond medicine.”Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC Bookmark
George Lundberg, MDArticle from OncLive curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.
Go to full article published by OncLive.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
No OS Boost With Opdivo in Recurrent Glioblastoma Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
Atezolizumab Plus Bevacizumab vs Sorafenib in Treatment-Naive Patients With Unresectable Hepatocellular Carcinoma Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
In a clinical trial, a combination of the drugs atezolizumab and bevacizumab improved both progression-free survival and overall survival in advanced hepatocarcinoma (the most common form of liver cancer), with fewer adverse effects. These findings were reported in the New England Journal of Medicine.
Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study Bookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.
Go to full paper published in the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 2, 2020
FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer Bookmark
George Lundberg, MDPress release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.
Go to full article published by the FDA.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.